Mechanism Integrin modulators [+6] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism αvβ1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Mechanism α5β1 antagonists [+4] |
Active Org. xCella Biosciences, Inc.Startup |
Originator Org. xCella Biosciences, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date24 Nov 2022 |
Sponsor / Collaborator- |
Start Date09 Nov 2022 |
Sponsor / Collaborator |
Start Date12 Jul 2022 |
Sponsor / Collaborator |